// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Evaluation of the ABC Pathway for Comprehensive Management of Atrial Fibrillation in 20,933 Patients from the ENGAGE AF-TIMI 48 Trial

Siddharth M Patel - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Edoxaban

Use of the “Pill in the Pocket” Approach for Atrial Fibrillation Termination as Determined from the Antiarrhythmic Medication for Atrial Fibrillation (AIM-AF) Study: A Physician Survey on the Prescription of Antiarrhythmic Drugs in the USA and Europe

James A Reiffel - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Treatment of Patients With Atrial Fibrillation and Heart Failure in the AIM-AF (Antiarrhythmic Medication for Atrial Fibrillation) Study: A Physician Survey on the Prescription of Antiarrhythmic Drugs in the US and Europe

Jonathan P Piccini - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Dronedarone

Role of Artificial Intelligence and Utilisation of Deep Learning Methods in Screening for Subcutaneous Implantable Cardioverter Defibrillator Eligibility

Mohamed ElRefai - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fragmented QRS is Independently Predictive of Long-Term Adverse Clinical Outcomes in Asian Patients Hospitalized for Heart Failure: A Retrospective Cohort Study

Jeffrey Shi Kai Chan - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Chronic Kidney Disease in the National Health and Nutrition Examination Survey (NHANES) 2017-2018 Data

Joanna Huang - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Dapagliflozin

A 7-Year Arterial Stiffness and Carotid Intima-Media Thickness Progression Predict Obesity, High Lean Mass, and Incident Hypertension from Age 17.7 to 24.5 Years: the ALSPAC Study

Andrew O Agbaje - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arterial stiffness

N/A

The ALPACA Study, an EHR Based Analysis of the Association of Elevated Alkaline Phosphatase With Cardiovascular Events

Philip Ambery - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Angiology

Acute Coronary Syndromes

Alkaline phosphatase

Three Year After Acute Coronary Syndrome, 6/10 of the Patients Are Treated in Accordance with International Guidelines in Middle East and North Africa: The Touraco Study

Mohamed Shoby - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Durable Reductions in Circulating Angiotensinogen and Blood Pressure Six Months After Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

Stephen Huang - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Demographic Differences in Hypertension and Its Treatment in Malawi

Saate S Shakil - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Age-Specific Threshold for Cardiovascular Disease Risk Stratification and Treatment Decision-Making

Zhe Xu - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessing the Applicability of Three Heart Failure Randomised Controlled Trials by Calibration to Scottish Registry

LILI WEI - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Life-Years Lost After Incident Atrial Fibrillation in Heart Failure

Nicklas Vinter - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Demographic and State-Level Trends in Mortality Due to Ischemic Heart Disease in the United States From 1999 to 2019

Mohammed Essa - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Coronary Artery Disease

N/A

Age-Related Demographic Trends in Mortality Due to Ischemic Heart Disease in the United States From 1999 to 2019

Mohammed Essa - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Progress Towards a Proteomic Surrogate Endpoint for Cardiovascular Outcomes

Stephen A Williams - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Periodontal Inflammation, Periodontal Bacterial Load and Virulence Genes Expression Are Risk Factors for Myocardial Infarction

Chaitanya Joshi - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Contemporary Evidence on Risk Stratification of Anticoagulated Non-Valvular Atrial Fibrillation Patients Grouped by Cha2D2-vasc Score Levels

Gregory Y Lip - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Non-valvular atrial fibrillation

rivaroxaban

National Trends of Atrial Fibrillation/Atrial Flutter Mortality in the United States From 1999 to 2019: Regional, Racial, and Gender Variations

Alireza Ghajar - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Arrhythmia

N/A

Copyright © 2026. QuantiNova All rights reserved